Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xarelto Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

J&J/Bayer’s Xarelto tested the limits of FDA’s policy on comparative efficacy, thanks to suboptimal use of the active comparator, warfarin, and the introduction of a new competitor, Pradaxa. In the medical reviewers’ view, new therapies should be as effective as existing therapies used skillfully, but division leadership would withhold approval only if the new drug were clearly inferior to approved agents.

Advertisement

Related Content

Savaysa Shows The Good And Bad Of Being Late In Class
Edoxaban Review ‘Not About Comparative Efficacy,’ FDA Says
FDA “Available Therapy” Determination Is A Moving Target, Industry Groups Say
Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate
Regulatory Round-Up: Drug Review Profiles From 2012
Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
ROCKET AF’s Design Causes Headaches For Xarelto Sponsors
Xarelto Review Puts FDA’s Comparative Effectiveness Stance To The Test
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel